Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016

Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which h...

Descripción completa

Detalles Bibliográficos
Autores principales: López, Roberto Ivan, Castro, Jenny Lissette, Cedeño, Heidy, Cisneros, Dagoberto, Corrales, Luis, González-Herrera, Ileana, Lima-Pérez, Mayté, Prestol, Rogelio, Salinas, Roberto, Soriano-García, Jorge Luis, T Zavala, Alejandra, Zetina, Luis Miguel, Zúñiga-Orlich, Carlos Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890062/
https://www.ncbi.nlm.nih.gov/pubmed/29636987
http://dx.doi.org/10.1136/esmoopen-2017-000315
_version_ 1783312793290670080
author López, Roberto Ivan
Castro, Jenny Lissette
Cedeño, Heidy
Cisneros, Dagoberto
Corrales, Luis
González-Herrera, Ileana
Lima-Pérez, Mayté
Prestol, Rogelio
Salinas, Roberto
Soriano-García, Jorge Luis
T Zavala, Alejandra
Zetina, Luis Miguel
Zúñiga-Orlich, Carlos Eduardo
author_facet López, Roberto Ivan
Castro, Jenny Lissette
Cedeño, Heidy
Cisneros, Dagoberto
Corrales, Luis
González-Herrera, Ileana
Lima-Pérez, Mayté
Prestol, Rogelio
Salinas, Roberto
Soriano-García, Jorge Luis
T Zavala, Alejandra
Zetina, Luis Miguel
Zúñiga-Orlich, Carlos Eduardo
author_sort López, Roberto Ivan
collection PubMed
description Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each patient. Each combination must seek to be effective and to generate the minimum adverse effects as possible. Instead of giving the first-line regimen until the tumour progresses, treatment is often individualised. Furthermore, up to 60% of colorectal tumours are considered non-mutated or wild-type CRC. Not harbouring mutations in the RAS family of genes or mutations in the signalling pathways of the epidermal growth factor receptor causes a null response to anti-epidermal growth factor receptor antibody therapy, which implies even more complex considerations regarding its management. The primary objective of this consensus is to address the main scenarios of mCRC in order to warrant the most appropriate therapeutic intervention for these patients in the Central American and the Caribbean (CAC) region. This can lead to better clinical outcomes as well as quality of life for palliative patients. This document includes the formal expert consensus recommendations for scenarios of mutated and non-mutated mCRC, including synchronous or metachronous disease, management of mCRC with liver and lung metastasis, resectable, potentially resectable or non-resectable tumours and local in the CAC context.
format Online
Article
Text
id pubmed-5890062
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58900622018-04-10 Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 López, Roberto Ivan Castro, Jenny Lissette Cedeño, Heidy Cisneros, Dagoberto Corrales, Luis González-Herrera, Ileana Lima-Pérez, Mayté Prestol, Rogelio Salinas, Roberto Soriano-García, Jorge Luis T Zavala, Alejandra Zetina, Luis Miguel Zúñiga-Orlich, Carlos Eduardo ESMO Open Review Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each patient. Each combination must seek to be effective and to generate the minimum adverse effects as possible. Instead of giving the first-line regimen until the tumour progresses, treatment is often individualised. Furthermore, up to 60% of colorectal tumours are considered non-mutated or wild-type CRC. Not harbouring mutations in the RAS family of genes or mutations in the signalling pathways of the epidermal growth factor receptor causes a null response to anti-epidermal growth factor receptor antibody therapy, which implies even more complex considerations regarding its management. The primary objective of this consensus is to address the main scenarios of mCRC in order to warrant the most appropriate therapeutic intervention for these patients in the Central American and the Caribbean (CAC) region. This can lead to better clinical outcomes as well as quality of life for palliative patients. This document includes the formal expert consensus recommendations for scenarios of mutated and non-mutated mCRC, including synchronous or metachronous disease, management of mCRC with liver and lung metastasis, resectable, potentially resectable or non-resectable tumours and local in the CAC context. BMJ Publishing Group 2018-03-15 /pmc/articles/PMC5890062/ /pubmed/29636987 http://dx.doi.org/10.1136/esmoopen-2017-000315 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
López, Roberto Ivan
Castro, Jenny Lissette
Cedeño, Heidy
Cisneros, Dagoberto
Corrales, Luis
González-Herrera, Ileana
Lima-Pérez, Mayté
Prestol, Rogelio
Salinas, Roberto
Soriano-García, Jorge Luis
T Zavala, Alejandra
Zetina, Luis Miguel
Zúñiga-Orlich, Carlos Eduardo
Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
title Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
title_full Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
title_fullStr Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
title_full_unstemmed Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
title_short Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
title_sort consensus on management of metastatic colorectal cancer in central america and the caribbean: san josé, costa rica, august 2016
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890062/
https://www.ncbi.nlm.nih.gov/pubmed/29636987
http://dx.doi.org/10.1136/esmoopen-2017-000315
work_keys_str_mv AT lopezrobertoivan consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT castrojennylissette consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT cedenoheidy consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT cisnerosdagoberto consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT corralesluis consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT gonzalezherreraileana consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT limaperezmayte consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT prestolrogelio consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT salinasroberto consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT sorianogarciajorgeluis consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT tzavalaalejandra consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT zetinaluismiguel consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016
AT zunigaorlichcarloseduardo consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016